Head to Head Comparison: BriaCell Therapeutics (OTCMKTS:BCTXF) and Eterna Therapeutics (NASDAQ:ERNA)

BriaCell Therapeutics (OTCMKTS:BCTXF) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Volatility & Risk

BriaCell Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.16, suggesting that its share price is 316% more volatile than the S&P 500.

Profitability

This table compares BriaCell Therapeutics and Eterna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	-786.77%
Eterna Therapeutics	N/A	-508.73%	-53.03%

Earnings and Valuation

This table compares BriaCell Therapeutics and Eterna Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	-$3.68 million	($3.84)	-0.71
Eterna Therapeutics	$70,000.00	170.03	-$21.67 million	($4.08)	-0.54

BriaCell Therapeutics has higher earnings, but lower revenue than Eterna Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 35.4% of Eterna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BriaCell Therapeutics and Eterna Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BriaCell Therapeutics	0	0	0	0	N/A
Eterna Therapeutics	0	0	0	0	N/A

Summary

Eterna Therapeutics beats BriaCell Therapeutics on 6 of the 9 factors compared between the two stocks.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

About Eterna Therapeutics

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.